Navigation Links
Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration
Date:4/28/2011

CLEVELAND, April 28, 2011 /PRNewswire/ -- A new study published online today in The New England Journal of Medicine (NEJM) shows bevacizumab (Avastin) is as effective as ranibizumab (Lucentis), the current Food and Drug Administration-approved drug for treating age-related macular degeneration (AMD).

The results are from the landmark "Comparison of AMD Treatments Trials" (CATT) study, a pioneering comparative effectiveness trial made possible through funding by the National Eye Institute.

"For years, ophthalmologists have been using intravitreal bevacizumab to treat neovascular AMD without data regarding efficacy and safety from well-controlled studies," said Daniel F. Martin, M.D., study chair for CATT and chairman of the Cole Eye Institute at Cleveland Clinic. "Patients and clinicians can now feel confident that bevacizumab is therapeutically equivalent to ranibizumab."

Derived from the same protein as bevacizumab – a well-known anti-cancer drug - ranibizumab was developed to block blood vessel growth in AMD patients. In 2005, two Genentech-sponsored clinical trials established ranibizumab as highly effective for the treatment of wet AMD. During the year between the announcement of the trial results and the release of ranibizumab, ophthalmologists began injecting AMD patients with low doses of bevacizumab due to its similarity to ranibizumab and its availability.  One dose of ranibizumab costs approximately $2,000, while bevacizumab costs about $50 per dose. Both drugs are manufactured by Genentech.  

Comparative effectiveness trials like (CATT) are necessary to the practice of evidence-based medicine, providing rigorous evaluation of the impact of different options that are available for treating a given medical condition for a particular set of patients.

Although funded with $1.1 billion through the 2009 American Recovery and Reinvestment Act, there remains insufficient infrastructure for the implementation of federally sponsored CER trials.

In the process of designing this trial, Dr. Martin and study co-chairs Maureen Maguire, Ph.D., and Stuart Fine, M.D., blazed a trail in comparative effectiveness research.

Facing a number of significant roadblocks to billing, payment and design, the CATT leadership proposed language to an amendment to the Medicare Improvements for Patients and Providers Act of 2008 to eliminate barriers to alternative payment mechanisms for NIH-sponsored trials. Although passed on July 15, 2008, there is still no defined Center for Medicare & Medicaid Services (CMS) process for initiating discussion of such alternative payment mechanisms.  

CATT found visual acuity improvement was virtually identical (within one letter difference on an eye chart) for either drug when given monthly.  In addition, no difference was found in the percentage of patients who had an important gain or loss in visual function. When each drug was given on an "as needed" (PRN) schedule, there also was no difference (within one letter) between drugs. PRN dosing required four to five fewer injections per year than monthly treatment but still resulted in substantial gains in vision. Visual gains were about two letters less with PRN than with monthly treatment but overall visual results were still excellent.

"In addition to the primary finding of equivalence between ranibizumab and bevacizumab for visual acuity, CATT also demonstrates that PRN dosing is a viable treatment option for either of these drugs," said Martin. "Substantial visual acuity gains may be accomplished with a lower treatment burden."

AMD is the leading cause of vision loss and blindness in older Americans. For many people, AMD severely impedes mobility and independence by limiting their ability to drive, read, recognize faces or perform tasks that require hand-eye coordination.

"Over 250,000 patients are treated each year for AMD and the majority receives bevacizumab. Given the lack of efficacy data regarding bevacizumab for AMD treatment, the NEI had an obligation to patients and clinicians to conduct this study," said Paul A. Sieving, M.D., Ph.D., director of the NEI. 

This and other findings from the Comparison of AMD Treatments Trials (CATT) will appear in the May 19, 2011 printed edition of The New England Journal of Medicine  CATT is funded by the National Eye Institute (NEI), a part of the National Institutes of Health.

About Cole Eye Institute

Cleveland Clinic Cole Eye Institute, which opened in November 1999, integrates clinical care, research and education in one 130,000-square-foot building. It includes five operating rooms, a 77-seat auditorium, 68 clinical suites, an expanded ophthalmic library, and state-of-the-art research laboratories. The institute is ranked among the Top 10 hospitals for eye care in the country by U.S. News & World Report in its annual hospital survey, making it No. 1 in Ohio.

About Cleveland Clinic

Celebrating its 90th anniversary, Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. It was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S. News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual "America's Best Hospitals" survey. About 2,800 full-time salaried physicians and researchers and 11,000 nurses represent 120 medical specialties and subspecialties. Cleveland Clinic Health System includes a main campus near downtown Cleveland, nine community hospitals and 15 Family Health Centers in Northeast Ohio, Cleveland Clinic Florida, the Lou Ruvo Center for Brain Health in Las Vegas, Cleveland Clinic Canada, and opening in 2013, Cleveland Clinic Abu Dhabi. In 2010, there were 4 million visits throughout the Cleveland Clinic health system and 155,000 hospital admissions. Patients came for treatment from every state and from more than 100 countries. Visit us at www.clevelandclinic.org.  Follow us at www.twitter.com/ClevelandClinic.


'/>"/>
SOURCE Cleveland Clinic
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. JumpStart Ventures Invests in Cleveland-based SPR Therapeutics
2. Michael Petras, Former CEO of GE Lighting, Named CEO of Cleveland-Based Specialty Medical Supplies Leader
3. NorTech, Crains Cleveland Business Announce 2011 Innovation Award Winners
4. JumpStart Ventures and Cleveland Clinic Invest in SironRX Therapeutics
5. Valence Health Selected by Cleveland Clinic to Support Clinical Integration Program
6. Cleveland Clinic Unveils Top 10 Medical Innovations for 2011
7. Carefx to Collaborate with the Cleveland Clinic to Commercialize CCF Business Intelligence Solution
8. Cleveland Clinic/Microsoft Pilot Promising; Home Health Services May Benefit Chronic Disease Management
9. OrthoWorx Urges Warsaws Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland
10. MyClyns(R) Now Available to Greater Clevelanders
11. Sonitus Medical Technology Ranks #1 on Cleveland Clinics Top 10 Medical Innovations for 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the ... Strategies" report to their offering. ... Pain Management in the ... their physical pain, emphasizing consumer survey analysis, including trends over ... adults who have selected illnesses/conditions strongly associated with physical pain ...
(Date:3/24/2017)... 24, 2017 ShangPharma, a leading ... cost-effective drug development and discovery services, technology, ... industry, announced today the intent for a ... be consolidating the Contract Research Organizations (CRO) ... ChemPartner. These entities include ChemPartner Shanghai, ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology:
(Date:3/24/2017)... , ... March 24, 2017 , ... ... Society (ONS) wanted to create a communications platform that positions them as the ... Elliance and ONS reinvented their online publication as an always-on, always-fresh news, views ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro ... their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is ... Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation ... and college Bible teacher residing in North Carolina with his wife, Anna Marie. He ... them with six grandchildren. David is also the author of “Shadow and Substance.” , ...
(Date:3/23/2017)... ... 2017 , ... The physicians of KSF Orthopaedic Center PA are proud to ... location is located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 ... provide patients living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The MBI “Hall of Fame” recognizes the ... acts have had a significant impact on the careers of all others involved. ... Inc. was inducted into the MBI’s Hall of Fame. The induction took place during ...
Breaking Medicine News(10 mins):